2024
Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Canadeo A, Giever E, Szabo A, Jin Y, Winer E, Badar T, Campos J, Lin C, Anderson C, Shallis R, Muradashvili T, Coltoff A, Guo Q, Patel A, Goldberg L, Abaza Y, Fariduddin M, Ayoub R, Foucar C, Nai N, Kota V, Dalgetty M, Gold M, Guduru M, Atallah E. Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium. Blood 2024, 144: 5174-5174. DOI: 10.1182/blood-2024-198914.Peer-Reviewed Original ResearchWhite blood cell countAcute promyelocytic leukemiaIncidence of relapseHigh-risk diseaseAll-Trans Retinoic AcidOverall survivalDifferentiation syndromeHigh riskArsenic trioxideInduction regimenTreatment regimensSupportive care strategiesCardiovascular comorbiditiesMedian white blood cell countData collection formDoses of gemtuzumab ozogamicinIncidence of CNS relapseIncidence of differentiation syndromeLow incidence of relapseOutcome of APL patientsSuspected acute promyelocytic leukemiaCumulative incidence of relapseDiagnosis of acute promyelocytic leukemiaLow-risk acute promyelocytic leukemiaMortality rateDyadic Yoga for Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers
Milbury K, Rosenthal D, Li Y, Ngo-Huang A, Mallaiah S, Yousuf S, Fuller C, Lewis C, Bruera E, Cohen L. Dyadic Yoga for Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers. Journal Of Pain And Symptom Management 2024, 67: 490-500. PMID: 38447621, PMCID: PMC11349719, DOI: 10.1016/j.jpainsymman.2024.02.565.Peer-Reviewed Original ResearchEmergency department visitsHead and neck cancerWaitlist controlHead and neck cancer patientsFamily caregiversYoga groupDepartment visitsYoga therapyHospital admissionPatient emergency department visitsPatient's last daysActive study participantsUnplanned hospital admissionsFeeding tube placementWaitlist control groupSupportive care strategiesQuality of lifeDyadic yogaYoga interventionYoga programCaregiver efficacyPilot RCTSF-36Care strategiesSymptom interference
2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kaesberg P, Kuykendall A, Madanat Y, McMahon B, Mohan S, Nadiminti K, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein B, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward D, Bergman M, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 1033-1062. PMID: 36075392, DOI: 10.6004/jnccn.2022.0046.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesMyeloproliferative neoplasmsClinical practice guidelinesEssential thrombocythemiaPolycythemia veraRisk stratificationManagement of myeloproliferative neoplasmsOverproduction of blood cellsPhiladelphia chromosome-negative myeloproliferative neoplasmsDiagnosis of myeloproliferative neoplasmsPractice guidelinesClonal blood disorderManagement of myelofibrosisCourse of treatmentSupportive care strategiesAssessment of symptomsNCCN guidelinesDiagnostic workupCare strategiesMultidisciplinary panelBlood disordersHeterogeneous groupSymptom statusBlood cellsNCCN
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply